date,title,source
Oct-18-18,Ultragenyx Announces Approval of Mepsevii (vestronidase alfa) in Brazil for the Treatment of Mucopolysaccharidosis VII,GlobeNewswire
Oct-22-18,Ultragenyx Announces Exclusive License to REGENXBIO AAV Vectors to Develop Gene Therapy for CDD (CDKL5 Deficiency Disorder),GlobeNewswire
Oct-26-18,Ultragenyx Announces Negative Topline Results from Phase 3 Study of UX007 in Patients with Glut1 DS with Disabling Movement Disorders,GlobeNewswire
Oct-30-18,Ultragenyx to Host Conference Call for Third Quarter 2018 Financial Results and Corporate Update,GlobeNewswire
